In yesterday’s Wall Street session, Cabaletta Bio Inc (NASDAQ:CABA) shares traded at $3.01, up 24.38% from the previous session.
CABA stock price is now -23.44% away from the 50-day moving average and -69.11% away from the 200-day moving average. The market capitalization of the company currently stands at $182.99M.
With the price target of $10, UBS recently initiated with Buy rating for Cabaletta Bio Inc (NASDAQ: CABA). On February 05, 2024, Jefferies recently initiated its ‘Buy’ rating on the stock quoting a target price of $36, while ‘William Blair’ rates the stock as ‘Outperform’
In other news, Binder Gwendolyn, insider sold 11,000 shares of the company’s stock on Jan 19 ’24. The stock was sold for $215,439 at an average price of $19.59. Upon completion of the transaction, the insider now directly owns 20,000 shares in the company, valued at $60200.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 19 ’23, Binder Gwendolyn sold 11,000 shares of the business’s stock. A total of $240,789 was realized by selling the stock at an average price of $21.89. This leaves the insider owning 20,000 shares of the company worth $60200.0. A total of 15.37% of the company’s stock is owned by insiders.
During the past 12 months, Cabaletta Bio Inc has had a low of $1.76 and a high of $26.35. As of last week, the company has a debt-to-equity ratio of 0.09, a current ratio of 8.11, and a quick ratio of 8.11. The fifty day moving average price for CABA is $3.9612 and a two-hundred day moving average price translates $9.8475 for the stock.
The latest earnings results from Cabaletta Bio Inc (NASDAQ: CABA) was released for 2024-06-30.
